Xi, Ziwei <br/><br/>
Ticagrelor Versus Clopidogrel in Patients with Two CYP2C19 Loss-of-Function Alleles Undergoing Percutaneous Coronary Intervention.  [electronic resource] 

 -  Cardiovascular drugs and therapy  04 2020 
 - 179-188 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7241 
<br/><br/><label>Standard No.: </label>10.1007/s10557-020-06956-4  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Clopidogrel--adverse effects<br/>Coronary Artery Disease--diagnostic imaging<br/>Coronary Thrombosis--mortality<br/>Cytochrome P-450 CYP2C19--genetics<br/>Female<br/>Hemorrhage--chemically induced<br/>Humans<br/>Male<br/>Middle Aged<br/>Myocardial Infarction--mortality<br/>Percutaneous Coronary Intervention--adverse effects<br/>Pharmacogenomic Variants<br/>Platelet Aggregation Inhibitors--adverse effects<br/>Purinergic P2Y Receptor Antagonists--adverse effects<br/>Registries<br/>Retrospective Studies<br/>Risk Assessment<br/>Risk Factors<br/>Stents<br/>Ticagrelor--adverse effects<br/>Time Factors<br/>Treatment Outcome